Dose escalation study of OMO-103, a first in class Pan-MYC-Inhibitor in patients (pts) with advanced solid tumors
Elena Garralda, V. Moreno, G. Alonso, E. Corral, Tatiana Hernández‐Guerrero, J. Ramon, B. Doger de Spéville, E. Martinez, L. Soucek, M. Niewel, E. Calvo
Topics & Concepts
MedicineChillsTolerabilityNauseaRashAdverse effectToxicityInternal medicineLimitingIn vivoOncologyMaximum tolerated doseCmaxPharmacokineticsPharmacologyGastroenterologyBiologyMechanical engineeringEngineeringBiotechnologyCancer Research and TreatmentsCancer Genomics and DiagnosticsPancreatic and Hepatic Oncology Research